Systemic treatment of Medullary thyroid carcinoma (MTC) is currently limited to the use of a tyrosine kinase inhibitor. Cytotoxic chemotherapy is not routinely recommended in the earlier lines of treatment due to the lack of efficacy. We describe a patient with locally advanced MTC who had an uncommon response to cisplatin and etoposide.
Introduction
Medullary thyroid carcinoma (MTC) is a well-differentiated thyroid cancer, which originates from the neuroendocrine parafollicular cells (C cells) [1] . Total thyroidectomy with central and bilateral functional neck dissection is recommended as a standard of care for resectable MTC [2] . Despite adequate surgical resection, only 43% of patients attained normal biochemistry, defined by normalization of serum calcitonin and CEA [3] . Although radioactive iodine (RAI) is an effective treatment for differentiated thyroid cancer, RAI is ineffective for MTC as C cells do not accumulate iodine [4] . External-beam radiotherapy (EBRT) may be of use in locoregional control after surgical resection for highrisk patients [4] . Metastatic or recurrent disease in patients who are not suitable for further surgical operations eventually requires systemic therapy with palliative intent. Systemic treatment of MTC is currently limited to the use of a tyrosine kinase inhibitor (TKI) which had resulted in various response rates (RR) of 28-45% and progression-free survival (PFS) ranging between 11.2 and 30.5 months [5] [6] [7] [8] [9] [10] . Several studies investigating the combination of cytotoxic chemotherapy for unresectable and/or metastatic MTC did not demonstrate any significant clinical benefits [4, [11] [12] [13] [14] . Therefore, cytotoxic chemotherapy is not routinely recommended for advanced MTC in the earlier lines of treatment due to the lack of efficacy. In this report, we describe a patient with locally advanced MTC who had an unexpected partial response to cisplatin and etoposide. The patient then underwent surgical resection and is currently on long-term follow-up care.
Case
A 52-year-old man presenting with an enlarged left neck mass, which had been rapidly growing for 2 months (March 2014). He denied any history of malignancy in the family. Physical examination showed several matted enlarged left cervical lymphadenopathy at levels II-V, measuring about 6 9 6 cm and 7 9 8 cm, respectively. Left thyroid nodule (3 9 3 cm) was also palpated. Other physical examinations were unremarkable. Computed tomography (CT) scan demonstrated multiple enlarged and matted lymph nodes (LNs) with various sizes along the left cervical levels II-V, left supraclavicular region and left superior mediastinum, measuring about 1.3-5.8 cm. These enlarged LNs partially encased the left common carotid artery. Multiple hypoechoic nodules were also found scattering in both lobes of thyroid gland, ranging between 0.5 and 2.9 cm, with the largest nodule containing cystic component situating at the lower pole of the left lobe (Fig. 1A and B) . Panendoscopy was also performed but yielded unremarkable results and multiple random negative biopsies. Fine-needle aspiration (FNA) of the left thyroid nodule revealed nodular goiter, with no malignant changes detected. Left cervical LN FNA showed metastatic carcinoma, which was suspicious for neuroendocrine carcinoma. Incisional biopsy of the left cervical LN demonstrated metastatic carcinoma with suspicious neuroendocrine feature. Immunohistochemical analysis revealed that the tumor cells expressed chromogranin A, CD56, CK7, and TTF-1. No expression of CK20, p63, CK5/6, and synaptophysin was observed. Ki-67 labeling index was 10%. These findings were consistent with metastatic neuroendocrine carcinoma of unknown primary.
The patient was then started on cisplatin (75 mg/ m 2 day 1) and etoposide (100 mg/m 2 day 1-3) every 3 weeks. After the 1st cycle, he had a dramatic response and achieved partial clinical response of the left cervical LNs. He subsequently completed three cycles of cisplatin and etoposide. Following the chemotherapy, the MRI scan of the head and neck revealed markedly decrease in size of the left cervical and supraclavicular LNs, with multiple stable thyroid nodules ( Fig. 1C and D) .
In were also present. The tumor cells contained granular cytoplasm and uniform round/oval nuclei with punctate chromatin (Fig. 2B) . Immunohistochemistry (IHC) stains confirmed the expression of calcitonin in tumor cells (Fig. 2C) . Serum calcitonin postoperatively was undetectable. After a final diagnosis of MTC was confirmed, the patient underwent complete thyroidectomy with right modified radical neck dissection type III and central neck dissection. Pathology report showed no residual MTC in both thyroid and right cervical LNs seen. He remained in remission with disease-free interval for 13 months.
In November 2015, he had a recurrence of enlarged left cervical LNs level IV and supraclavicular lymphadenopathy ( Fig. 3A and B) . Serum calcitonin and CEA were also elevated (Fig. 4) . FNA confirmed neoplastic cells with neuroendocrine feature. He achieved partial response with three cycles of cisplatin and etoposide and subsequently underwent salvage surgery of the left cervical lymphadenopathy ( Fig. 3C and D) . Pathology revealed 
Discussion
Medullary thyroid carcinoma is less often associated with hereditary multiple endocrine neoplasia (MEN) type 2 syndromes (MEN2A and MEN2B), with the majority of MTC cases (approximately 75%) being sporadic [10] .
RET proto-oncogene is the dominant oncogene in MTC. Activating germ line mutations of the RET proto-oncogene is associated with almost all patients with MEN2A and MEN2B. In sporadic MTC, somatic RET mutations are the most common driver in genetic alterations, followed by RAS mutations and RET or ALK fusions [10] . In addition, angiogenesis plays a significant role in tumor growth, proliferation and metastasis [4] . Thus, several tyrosine kinase inhibitors (TKIs) targeting RET and vascular endothelial growth factor (VEGF) pathways were evaluated in clinical studies, which led to the US FDA approval of vandetanib and cabozantinib for recurrent/metastatic MTC [10] . Vandetanib and cabozantinib significantly improved PFS from 19.3 to 30.5 months (HR 0.59: 95% CI: 0.31-0.69; P < 0.001), and 4.0-11.2 months (HR 0.28: 95% CI: 0.19-0.40; P < 0.001), respectively, when compared with a placebo [5, 8] . Other TKIs such as sorafenib and lenvatinib also demonstrated clinical activity in recurrent/metastatic MTC patients [6, 9] . Prior to the era of targeted therapy, cytotoxic chemotherapy was used for metastatic MTC in a palliative setting with limited antitumor activity [4] . Doxorubicinbased chemotherapy and dacarbazine-based chemotherapy were the most extensively studied regimens. In a small subset of prospective phase II study of doxorubicin for advanced thyroid cancer, 10 patients with MTC were treated with doxorubicin with or without cisplatin [11] . Three patients demonstrated partial response (PR). Another small phase II study of doxorubicin in combination with cisplatin and vincristine demonstrated PR in only one of 10 metastatic MTC patients [12] .
Dacarbazine is an alkylating agent, which was evaluated in combination with cyclophosphamide and vincristine for treatment of advanced MTC [13] . Two of seven patients achieved PR and biochemical response for 14 and 29 months. In addition, combination of dacarbazine and 5-fluorouracil demonstrated PR in three of five metastatic MTC patients and lasted for 8-10 months [14] . Recently, a good response from a combination of capecitabine and temozolominde was reported in metastatic MTC patient, based on the efficacy of the combination of dacarbazine and 5-fluorouracil [15] Temozolomide and dacarbazine are prodrugs of the active alkylating agent 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide, which could be used alternatively. Similarly, capecitabine is a prodrug of 5-fluorouracil. Here, we described an uncommon response to the combination of cisplatin and etoposide in advanced MTC patient, who was initially misdiagnosed as a neuroendocrine tumor (NET) of unknown primary. Cisplatin (75 mg/m 2 Day 1) and etoposide (100 mg/m 2 Day 1-3) regimens are routinely used as a standard treatment for advanced high-grade gastrointestinal NET and small-cell lung cancer (SCLC) [16] . Although MTC is considered as a neuroendocrine tumor of thyroid arising from C cells, the standard treatment of MTC is different from other NETs [10, 16] . NETs generally cover heterogeneous subtypes of tumor with a wide range of clinical behavior and genetic alterations [16] . Histopathological classification separates well-differentiated (grade 1/2) versus poorly differentiated NET to guide physicians for treatment selection. Well-differentiated NET may respond to targeted therapies involving the VEGF and mTOR pathways, whereas platinumbased chemotherapy is the mainstay treatment for poorly differentiated NET [16] . In this particular case, the patient presented with rapidly progressive bulky lymphadenopathy, which behaved like poorly differentiated NET or SCLC. We speculated that the response to chemotherapy in this case might be related to poorly differentiated NET component of the tumor. To our knowledge, this is the first report of clinical activity of the combination of cisplatin and etoposide in advanced MTC patient. As MTC is considered as a NET of thyroid, using platinum-based chemotherapy regimens for poorly differentiated NET might be of benefit for selected advanced MTC patients who failed standard targeted therapies.
Conclusion
In the current era of targeted therapy, uncommon response to cisplatin and etoposide as treatment for advanced MTC was observed in this report. Therefore, the benefits of platinum-based chemotherapy regimens used for poorly differentiated NETs or SCLC should be further explored in selected advanced MTC patients who had failed standard targeted therapy.
